Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly EBT Margin came in at 123.7% in Q1 2026, up 13310.0% YoY from N/an in Q1 2025, and up 233.71% on a QoQ basis from 37.07% in Q4 2025.
Zevra Therapeutics (ZVRA) EBT Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of EBT Margin data on file, last reported at 123.7% in Q1 2026.
- Quarterly EBT Margin rose 13310.0% year-over-year to 123.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109.04% (up 29510.0% YoY) and the FY2025 annual result came in at 81.41%, up 46317.0% from the prior year.
- EBT Margin rose to 123.7% in Q1 2026, from 37.07% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 297.15% in Q2 2025 to a low of 1751.76% in Q2 2022.
- A 5-year average of 289.18% and a median of 161.76% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 180351 bps — and 2023, when it jumped 172051 bps.
- Tracing ZVRA's EBT Margin over 5 years: stood at 148.66% in 2022, then decreased by 4 bps to 153.96% in 2023, then retreated by 10 bps to 169.56% in 2024, then soared by 122 bps to 37.07% in 2025, then jumped by 234 bps to 123.7% in 2026.
- The last three EBT Margin figures came in at 123.7% (Q1 2026), 37.07% (Q4 2025), and 3.75% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 32.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.23% |
| Mar 31, 2026 | 123.70% |
| Dec 31, 2025 | 37.07% |
| Sep 30, 2025 | -3.75% |
| Jun 30, 2025 | 297.15% |
| Mar 31, 2025 | -9.40% |
| Dec 31, 2024 | -169.56% |
| Sep 30, 2024 | -899.19% |
| Jun 30, 2024 | -451.25% |
| Mar 31, 2024 | -487.36% |
| Dec 31, 2023 | -153.96% |
| Sep 30, 2023 | -351.99% |
| Jun 30, 2023 | -31.25% |
| Mar 31, 2023 | -419.40% |
| Dec 31, 2022 | -148.66% |
| Sep 30, 2022 | -207.20% |
| Jun 30, 2022 | -1,751.76% |
| Dec 31, 2021 | -103.37% |
| Sep 30, 2021 | -89.52% |
| Jun 30, 2021 | 51.75% |